After a week of waiting, the immunohistochemistry result and FISH result in bed 18 finally came out. ER(-), PR(-), Her-2(++++), FISH showed positive Her-2 amplification. She was a 32-year-old female with a 2.6*2.3 cm mass, no metastasis in axillary lymph nodes (0/10), Ki67 50%, no metastases on CT of head, chest and abdomen, and no metastases on bone scan, diagnosing stage IIA invasive ductal carcinoma of the breast (Her-2 amplified). Being younger than 35 years old, she belonged to young breast cancer, which is a risk factor. a high Ki67 ratio indicated both a high proliferative capacity of the tumor, yet presumably she was sensitive to chemotherapy. Fortunately, the axillary lymph nodes had not metastasized and after discussion, we decided to put her on EC*4 times->PH*4 times chemotherapy, i.e. 4 bands of epi-amycin + cyclophosphamide, sequential 4 bands of paclitaxel + Herceptin treatment, every 3 weeks. There are two things that should be noted during chemotherapy: 1. Since both epi-adriamycin and Herceptin have the ability to damage the heart, so we first performed cardiac ultrasound to understand the patient’s basal heart function, and secondly, we used Ono first with epi-adriamycin to reduce the damage of chemotherapy drugs on the heart. 2, the patient is a hepatitis B virus carrier, i.e., small triple-positive, chemotherapy on the body’s immunity will lead to the possibility of HVB virus replication. So first we know the basal HBV-DNA copy number before chemotherapy, and apply Herceptin prophylaxis during chemotherapy, and regularly observe the patient’s liver function changes and HBV-DNA changes.